Cargando…

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis

BACKGROUND: Outcome data on simeprevir and sofosbuvir (SMV+SOF) in patients with liver transplantation (LT) with hepatitis C virus genotype 1 (HCV-1) are limited with individual studies having a small sample size and limited SVR12 (sustained virological response) data. Our goal was to perform a meta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Nghia H, Yee, Brittany E, Chang, Christine, Jin, Minjuan, Lutchman, Glen, Lim, Joseph K, Nguyen, Mindie H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782279/ https://www.ncbi.nlm.nih.gov/pubmed/26966549 http://dx.doi.org/10.1136/bmjgast-2015-000066

Ejemplares similares

Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials
por: Yee, Brittany E, et al.
Publicado: (2016)

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis
por: Yee, Brittany E, et al.
Publicado: (2015)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care
por: Vu, Vinh D, et al.
Publicado: (2015)

Treatment of Recurrent Hepatitis C Genotype-4 Post-Liver Transplantation with Sofosbuvir plus Simeprevir
por: Ascha, Mustafa, et al.
Publicado: (2015)

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience
por: Nguyen, Peter, et al.
Publicado: (2017)

Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C
por: Sarkar, Souvik, et al.
Publicado: (2015)

Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation
por: Khemichian, Saro, et al.
Publicado: (2015)

Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study
por: Ladenheim, Maya R, et al.
Publicado: (2016)

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations
por: Gilman, Andrew J, et al.
Publicado: (2018)

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation
por: Issa, D., et al.
Publicado: (2016)

STAT4-associated natural killer cell tolerance following liver transplantation
por: Jamil, K M, et al.
Publicado: (2017)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia
por: Kim, Yoona A, et al.
Publicado: (2016)

Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt
por: Shiha, Gamal, et al.
Publicado: (2019)

Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
por: Welzel, Tania M, et al.
Publicado: (2016)

Application of different spectrophotometric methods for quantitative analysis of direct acting antiviral drugs simeprevir and sofosbuvir
por: Ramzy, Sherif, et al.
Publicado: (2022)

Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators
por: Van, Nguyen Dinh, et al.
Publicado: (2016)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
por: Gaetano, John N
Publicado: (2014)

Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C
por: Eyre, Zachary W., et al.
Publicado: (2016)

Sofosbuvir in combination with ribavirin or simeprevir: real-life study of patients with hepatitis C genotype 4
por: Abdel-Moneim, Adel, et al.
Publicado: (2019)

Successful Treatment of Hepatitis C with Simeprevir, Sofosbuvir, and Ribavirin in an HIV Coinfected Liver Transplant Patient with Advanced Chronic Kidney Disease
por: Maruyama, Anna, et al.
Publicado: (2016)

Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report
por: Ende, Alexander R., et al.
Publicado: (2015)

Unexpected clinical outcomes following the implementation of a standardised order set for hepatic encephalopathy
por: KC, Mandip, et al.
Publicado: (2021)

Preoperative serum hepatitis B virus DNA was a risk factor for hepatocellular carcinoma recurrence after liver transplantation
por: Zhang, Dali, et al.
Publicado: (2022)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
por: Walker, David R, et al.
Publicado: (2015)

Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
por: Obed, Aiman, et al.
Publicado: (2016)

Updated upper limit of normal for serum alanine aminotransferase value in Vietnamese population
por: Huong, Nguyen Thi Cam, et al.
Publicado: (2022)

Obstacles to the deceased donor transplantation in Pakistan
por: Ullah, Kaleem, et al.
Publicado: (2023)

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results
por: Bichoupan, Kian, et al.
Publicado: (2017)

Liver transplantation for hepatocellular carcinoma beyond the Milan criteria
por: Xu, Xiao, et al.
Publicado: (2016)

Does COVID-19 infection significantly affect liver transplantation? Results of liver transplantation in the COVID-19 era at a single, high-volume centre
por: Moradi, Alimohammad, et al.
Publicado: (2023)

Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis
por: Harms, Maren H, et al.
Publicado: (2020)

Influence of sex in alcohol‐related liver disease: Pre‐clinical and clinical settings
por: Bizzaro, Debora, et al.
Publicado: (2023)

A novel prognostic model for transplant-free survival in primary sclerosing cholangitis
por: de Vries, Elisabeth M, et al.
Publicado: (2018)

Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance
por: Meng, Chao-Yang, et al.
Publicado: (2023)

Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis
por: Rivas, Gloriany, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_et0blgtccvvn40jl70sm984sur